Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at JonesTrading from a “hold” rating to a “buy” rating in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a $29.00 price objective on the stock. JonesTrading’s target price suggests a potential upside of 113.24% from the stock’s previous close.

Several other research firms have also issued reports on NTLA. Brookline Capital Acquisition reissued a “buy” rating on shares of Intellia Therapeutics in a research note on Tuesday. Barclays reduced their price target on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, November 7th. KeyCorp set a $25.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, January 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, January 22nd. Finally, Wolfe Research reissued a “peer perform” rating on shares of Intellia Therapeutics in a research note on Wednesday, November 12th. Eleven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $19.59.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $13.60 on Wednesday. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25. The stock has a market capitalization of $1.61 billion, a P/E ratio of -3.55 and a beta of 2.10. The firm’s 50-day moving average is $12.09 and its two-hundred day moving average is $13.10.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The firm had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. During the same quarter last year, the company posted ($1.27) EPS. The firm’s quarterly revenue was up 78.4% on a year-over-year basis. As a group, analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Activity at Intellia Therapeutics

In related news, EVP James Basta sold 10,397 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $95,756.37. Following the transaction, the executive vice president directly owned 101,528 shares of the company’s stock, valued at $935,072.88. This trade represents a 9.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the sale, the executive vice president directly owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 53,051 shares of company stock valued at $488,600 over the last three months. 3.10% of the stock is owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC boosted its position in shares of Intellia Therapeutics by 154.1% in the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after purchasing an additional 55,118 shares during the period. Woodline Partners LP purchased a new position in Intellia Therapeutics during the 1st quarter worth $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Intellia Therapeutics by 8.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after purchasing an additional 38,521 shares during the period. Atria Investments Inc purchased a new stake in shares of Intellia Therapeutics in the second quarter valued at about $96,000. Finally, Vestmark Advisory Solutions Inc. raised its holdings in shares of Intellia Therapeutics by 104.7% in the second quarter. Vestmark Advisory Solutions Inc. now owns 638,342 shares of the company’s stock valued at $5,988,000 after buying an additional 326,460 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removes the clinical hold on Intellia’s MAGNITUDE Phase 3 trial for nexiguran ziclumeran (nex‑z) in ATTR‑CM — a major regulatory clearing that re‑enables a late‑stage program and reduces a regulatory overhang. US FDA lifts clinical hold (Reuters)
• Positive Sentiment: Multiple analyst upgrades and price‑target increases this week (William Blair upgraded to Outperform; HC Wainwright, Leerink, Citizens JMP and others raised targets), which signal continuing buy‑side conviction and potential upside over the medium term. William Blair upgrade (American Banking News) Multiple price target moves (Benzinga)
• Positive Sentiment: Company presented longer‑term clinical and patient‑reported data on lonvoguran ziclumeran (lonvo‑z) at AAAAI (3‑year follow‑up and HAE patient burden research), supporting the durability and commercial case for that program. AAAAI data release (GlobeNewswire)
• Neutral Sentiment: Visible investor interest from notable buyers (e.g., coverage that highlighted institutional purchases such as Cathie Wood’s funds) — supports liquidity and attention but not an immediate directional determinant. Cathie Wood buying note (The Motley Fool)
• Negative Sentiment: HC Wainwright trimmed near‑term and full‑year EPS forecasts (Q1/Q3/Q4 and FY2026 nudged lower), citing updated modeling; even though they maintained a Buy and raised a price target, the EPS cuts suggest slower near‑term financial performance and appear to have pressured sentiment. HC Wainwright estimate changes (MarketBeat)
• Negative Sentiment: After recent positive headlines and upgrades, the stock has seen short‑term profit‑taking and volatility; the combination of modest EPS downgrades plus traders locking gains likely explains the intraday decline despite longer‑term catalysts.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.